CMCamila Vilas Boas Machado

Camila Vilas Boas Machado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camila Vilas Boas Machado has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Espectro dos achados de imagem na cardiomiopatia de takotsubo: um ensaio iconográfico

    by Camila Vilas Boas Machado, Roberto Sasdelli Neto, Gilberto Szarf, Walther Yoshiharu Ishikawa, Eduardo Kaiser Ururahy Nunes Fonseca

    Resumo A cardiomiopatia de takotsubo é um diagnóstico diferencial importante de dor torácica aguda. Exames de imagem, seja por ventri-culografia, ecocardiograma, tomografia computadorizada do coração ou ressonância magnética cardíaca, são ferramentas valiosas para a confirmação diagnostica nesse contexto. O presente estudo revisa a literatura e exemplifica o espectro dos achados típicos e atípicos dessa doença observados na ressonância magnética cardíaca, com base na experiência do nosso serviço. O reconhecimento dessas características reforça o papel do médico radiologista/cardiologista na linha de cuidado de pacientes com dor torácica aguda, possibilitando o diagnóstico e tratamento adequado.

  • Open Access

    The spectrum of imaging findings in takotsubo cardiomyopathy: a pictorial essay

    by Camila Vilas Boas Machado, Roberto Sasdelli Neto, Gilberto Szarf, Walther Yoshiharu Ishikawa, Eduardo Kaiser Ururahy Nunes Fonseca

    Takotsubo cardiomyopathy is an important differential diagnosis for acute chest pain. Imaging tests, such as ventriculography, echocardiography, computed tomography of the heart, and cardiac magnetic resonance, are valuable tools for diagnostic confirmation in this context. This study reviews the literature and exemplifies the spectrum of typical and atypical cardiac magnetic resonance findings in this disease, on the basis of the experience of our facility. Recognition of these characteristics underscores the roles that radiologists and cardiologists play in the care of patients with acute chest pain, enabling an accurate diagnosis and appropriate treatment.

  • Open Access

    Look-Locker T1 relaxometry and high-resolution T2 in the evaluation of lung lesions: a single-center prospective study

    by Danilo Tadao Wada, Li Siyuan Wada, Camila Vilas Boas Machado, Mateus Repolês Lourenço, Tales Rubens de Nadai, Federico Enrique Garcia Cipriano, Alexandre Todorovic Fabro, Marcel Koenigkam-Santos

    Objective: To explore the feasibility of two magnetic resonance imaging (MRI) sequences—high-resolution T2-weighted (HR T2) and Look-Locker T1 (LL T1) relaxometry—for the investigation focal lung lesions (FLLs). As a secondary objective, we analyzed the diagnostic accuracy of these sequences. Materials and Methods: This was a prospective observational study involving 39 subjects with FLLs scanned in a 1.5-T MRI system with LL T1 relaxometry and HR T2 sequences focused on the FLL region, in addition to a conventional protocol. All images were evaluated by two radiologists, working independently, who were blinded to other findings. Results: Most of the examinations (31 of the LL T1 relaxometry sequences and 36 of the HR T2 sequences) were of adequate diagnostic quality. Nondiagnostic examinations were considered so mainly because of limited coverage of the sequences. Of the FLLs studied, 19 were malignant, 17 were benign, and three were excluded from the accuracy analysis because there was no definitive diagnosis. Although LL T1 relaxometry could not distinguish between benign and malignant lesions, the signal intensity at its first inversion time (160 ms) differed between the two groups. The HR T2 sequence was considered the best sequence for assessing specific morphological characteristics, especially pseudocavities and pleural tags. We found that MRI showed better accuracy than did computed tomography (86% vs. 74%). Conclusion: Both MRI sequences are feasible for the evaluation of FLLs. Images at 160 ms of the LL T1 relaxometry sequence helped distinguish between benign and malignant lesions, and the HR T2 sequence was considered the best sequence for evaluating specific morphological characteristics.


  • Open Access

    Radiomic analysis of lung cancer for the assessment of patient prognosis and intratumor heterogeneity

    by José Raniery Ferreira Junior, Marcel Koenigkam-Santos, Camila Vilas Boas Machado, Matheus Calil Faleiros, Natália Santana Chiari Correia, Federico Enrique Garcia Cipriano, Alexandre Todorovic Fabro, Paulo Mazzoncini de Azevedo-Marques

    Objective: To determine whether the radiomic features of lung lesions on computed tomography correlate with overall survival in lung cancer patients. Materials and Methods: This was a retrospective study involving 101 consecutive patients with malignant neoplasms confirmed by biopsy or surgery. On computed tomography images, the lesions were submitted to semi-automated segmentation and were characterized on the basis of 2,465 radiomic variables. The prognostic assessment was based on Kaplan-Meier analysis and log-rank tests, according to the median value of the radiomic variables. Results: Of the 101 patients evaluated, 28 died (16 dying from lung cancer), and 73 were censored, with a mean overall survival time of 1,819.4 days (95% confidence interval [95% CI]: 1,481.2-2,157.5). One radiomic feature (the mean of the Fourier transform) presented a difference on Kaplan-Meier curves (p < 0.05). A high-risk group of patients was identified on the basis of high values for the mean of the Fourier transform. In that group, the mean survival time was 1,465.4 days (95% CI: 985.2-1,945.6), with a hazard ratio of 2.12 (95% CI: 1.01-4.48). We also identified a low-risk group, in which the mean of the Fourier transform was low (mean survival time of 2,164.8 days; 95% CI: 1,745.4-2,584.1). Conclusion: A radiomic signature based on the Fourier transform correlates with overall survival, representing a prognostic biomarker for risk stratification in patients with lung cancer.